Ipsen to announce new data from CLARINET FORTE study at ENETS Conference

Ipsen announced a total of 9 abstracts presenting new data with a focus in NETs. These include data from the Phase II CLARINET FORTE study and data on the use of independent administration of lanreotide autogel to be presented at the ENETS Conference, taking place virtually February 25-27. Updated data from the CLARINET FORTE study were presented including additional quality of life, or QoL, data showcasing assessments of patients' perceived QoL during the treatment period of the study. QoL was assessed using three validated questionnaires covering the severity of problems associated with mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, or EQ-5D-5L, as well as questionnaires specific to patients with cancer, or EORTC QLQ-C30, and NETs. Results from these measurements suggest no deterioration of QoL with no substantial deviation from baseline prior to treatment. Additional pharmacokinetic, or PK, analyses of the increased dosing regimen showed that PK increased in a proportional manner and no increase in rates of glycoregulation, cholelithiasis or hypertension in patients with increased lanreotide autogel exposure was observed. With confirmation of the PK data together with the substantial period of QoL preservation, data from the CLARINET FORTE study could represent a potentially meaningful treatment option for a population of patients with high unmet needs. Among the Ipsen data presented at ENETS 2021 is the presentation of findings from a study into the potential cost savings associated with increased uptake of independent administration of long-acting somatostatin analogues, or SSAs, for the treatment of gastroenteropancreatic NETs, or GEP-NETs, within the UK's National Healthcare Service, or NHS. In the UK, lanreotide autogel is approved for independent injection at home by the patient or a partner. Health-economic modeling suggests that when a patient with GEP-NETs treated with octreotide long-acting release, or LAR, transition to lanreotide autogel administered via independent injection, an average of 14.5 nurse contacts, including four hospital visits, could potentially be avoided every year as well as potential overall expenses per patient being lowered by 16.4% equating to GBP 2,458 saved per year. At a population level, the increase in patients independently injecting SSAs, from 12.6% to 24.5%, may have reduced the annual overall healthcare expenditure for the NHS from GBP 53.4M to GBP 52.9M.Ipsen also unveiled details from multiple studies highlighting a data-driven vision of patient-centricity, which show how mining the wealth of data generated from a drug's discovery to real-world use after regulatory approval can unlock insights into the epidemiology and clinical features of NETs. These include a retrospective study leveraging data from five years of electronic health records to increase understanding of NETs and help to identify new therapeutic strategies; and results from the Phase III RAISE study investigating the use of deep learning models and dissociated response to predict early treatment efficacy in patients with NETs.